In the present work, we propose the molecule ACE2-hFcLALA, based on ECD ACE2 (aa 18–740) and Fc (IgG1) with mutations L234A and L235A, as a candidate for the therapy against COVID-19. This evidence concerns the gene ACE2 and COVID-19.